PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-21.17%
Cash & equivalents declining -21.17% while Medical - Pharmaceuticals shows 0.00% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-21.17%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -5.75%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
-1.19%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
8.24%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-8.14%
Below half the Medical - Pharmaceuticals median of 0.00%. Jim Chanos would question if the company faces working capital strain.
4.15%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.34%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
10.30%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
10.30%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.92%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.60%
≥ 1.5x the Medical - Pharmaceuticals median of 0.18%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-2.57%
Below half the Medical - Pharmaceuticals median of 0.50%. Jim Chanos might see potential stagnation or distress vs. peers.
-3.45%
Payables growth above 1.5x Medical - Pharmaceuticals median of -1.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-4.42%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-29.43%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-29.11%
≥ 1.5x the Medical - Pharmaceuticals median of -4.73%. Joel Greenblatt sees a robust subscription base vs. peers.
-12.60%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-6.14%
Below half Medical - Pharmaceuticals median of 0.92%. Joel Greenblatt sees more conservative short-term leverage than peers.
-22.28%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.56%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-8.87%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-6.41%
Below half Medical - Pharmaceuticals median of 1.42%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
5.49%
≥ 1.5x Medical - Pharmaceuticals median of 1.86%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.07%
≥ 1.5x Medical - Pharmaceuticals median of 1.12%. Joel Greenblatt sees stronger equity growth vs. peers.
-2.57%
Below half Medical - Pharmaceuticals median of 0.50%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
-13.18%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
23.70%
Above 1.5x Medical - Pharmaceuticals median 3.62%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.